[Skip to Navigation]
November 2017

Secukinumab-Induced Psoriasiform Eruption

Author Affiliations
  • 1University of Tasmania, South Launceston, Tasmania, Australia
  • 2Memorial University of Newfoundland, St John’s, Newfoundland and Labrador, Canada
JAMA Dermatol. 2017;153(11):1194-1195. doi:10.1001/jamadermatol.2017.2826

Tumor necrosis factor (TNF) and interleukin (IL)-12/23 (ustekinumab) blockade are highly effective treatments for many autoimmune conditions including psoriasis, but rarely these agents can paradoxically induce psoriasiform eruptions.1-4 Interestingly, ustekinumab has been shown to control TNF inhibitor–induced psoriasis,2 and TNF inhibitors have been shown to control ustekinumab-induced psoriasis,4 supporting the hypothesis of multiple pathways in psoriasis with one or the other being most important in an individual patient. If this is true, then if an individual experiences disease flares with one class of biological agent, a treatment response may be achieved with another class.

Add or change institution